Foghorn Therapeutics Inc. (FHTX) Operating income 2019–2025
Foghorn Therapeutics Inc. (FHTX) annual operating income history from SEC filings — each fiscal year as reported.
-$86.4MFY2025 · since FY2019: -$51.1M → -$86.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$86.4M | +15.9% |
| FY2024 | -$102.7M | +4.8% |
| FY2023 | -$107.9M | +7.9% |
| FY2022 | -$117.1M | -16.3% |
| FY2021 | -$100.7M | -47.0% |
| FY2020 | -$68.5M | -34.2% |
| FY2019 | -$51.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More FHTX financial trends
FHTX RevenueFHTX Net incomeFHTX Net marginFHTX Gross profitFHTX Gross marginFHTX Operating marginFHTX Operating cash flowFHTX Free cash flowFHTX Capital expendituresFHTX Return on equityFHTX Stock buybacksFHTX Dividends paidFHTX Total assetsFHTX Total liabilitiesFHTX Shareholders’ equityFHTX overview →